PhagoMed selected for Phase III of EIT Health's Gold Track program
Since June 2020, PhagoMed has been part of the Gold Track program, the premier European life sciences accelerator. Following the successful completion of Phase II of the program and a presentation in front of the Executive Council on February 18th, PhagoMed was re-selected as a member of the Gold Track program for the third and final program phase. PhagoMed is only the third company in the history of Gold Track to advance to the final stage of the program.
The company joins four other visionary healthcare start-ups in the current cohort of the program. Each start-up had to prove the viability of their innovations and business plans in the competitive EIT Health Gold Track workshop. As part of the Gold Track program PhagoMed will once again receive individualized and tailored mentoring by industry giants, to support the further acceleration of our research programs and our fundraising efforts.
The Gold Track program selects between 10 and 15 European Lifescience companies every year. These companies receive world-class mentoring and tailor-made exposure to potential investors and industry partners around the world. For more information on the Gold Track program, please follow this link.